Leukapheresis ( DrugBank: - )

5 diseases

49. 全身性エリテマトーデス

臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00230035 (ClinicalTrials.gov)	September 2005	28/9/2005	Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)	A Randomized, Open Label, Phase II Multicenter Study of Non-Myeloablative Autologous Transplantation With Auto-CD34+HPC Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Procedure: Leukapheresis;Procedure: Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT);Procedure: Autologous CD34+HPC transplantation (HSCT);Procedure: Plasmapheresis;Drug: Rabbit anti-thymocyte globulin;Drug: Methylprednisolone;Drug: Growth colony stimulating factor (G-CSF);Drug: Corticosteroids;Drug: Mycophenolate mofetil;Drug: Azathioprine;Drug: Intravenous immunoglobulin;Drug: Methotrexate;Drug: Rituximab;Drug: Leflunomide	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Withdrawn	18 Years	60 Years	Both	0	Phase 2	United States

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00040651 (ClinicalTrials.gov)	July 2002	5/7/2002	Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients	Transplantation With T-Cell Depleted Autologous Peripheral Stem Cells for Severe Systemic Sclerosis: A Phase I Dose Escalation Study	Scleroderma;Systemic Sclerosis	Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Thymoglobulin;Procedure: Leukapheresis;Procedure: Self bone marrow transplant	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	University of Pittsburgh;Amgen;Genzyme, a Sanofi Company	Terminated	18 Years	70 Years	Both	15	Phase 1	United States

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04224558 (ClinicalTrials.gov)	December 15, 2020	4/4/2018	Stem Cell Transplantation in Crohn's Disease	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease	Crohn Disease	Drug: Mesna;Drug: Cyclophosphamide;Drug: Filgrastim;Procedure: Apheresis catheter placement;Procedure: Leukapheresis;Drug: Fludarabine;Drug: Methylprednisolone;Drug: Diphenhydramine;Drug: Acetaminophen;Drug: anti-thymocyte globulin (rabbit);Drug: lymphocyte immune globulin;Biological: Peripheral Blood Stem Cell Infusion;Drug: Cytoxan	Cedars-Sinai Medical Center	NULL	Recruiting	13 Years	28 Years	All	15	Phase 1/Phase 2	United States
2	NCT02676622 (ClinicalTrials.gov)	April 2013	21/4/2013	Autologous Stem Cell Transplant for Refractory Crohn's Disease	A Pilot Study of Autologous Hematopoietic Stem Cell Transplantation With Post-Transplant Ultra Low-Dose IL-2 for Refractory Crohn's Disease	Crohn's Disease	Drug: mobilization of stem cells to prepare for Leukapheresis;Other: Leukapheresis- Collection of stem cells;Drug: Preparative regimen 4-6 weeks after Leukapheresis;Other: Stem Cell Transplant;Drug: Low-dose IL-2 administration	Nationwide Children's Hospital	NULL	Withdrawn	12 Years	29 Years	All	0	Phase 2	NULL

臨床試験数 : 37 / 薬物数 : 110 - (DrugBank : 34) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00011505 (ClinicalTrials.gov)	February 2001	22/2/2001	Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia	Investigation of G-CSF-Induced Stem Cell Mobilization Potential in Patients With Diamond-Blackfan Anemia	Diamond Blackfan Anemia	Drug: G-CSF;Procedure: Leukapheresis	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	N/A	N/A	Both	15	Phase 2	United States

臨床試験数 : 59 / 薬物数 : 118 - (DrugBank : 32) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 155

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01331018 (ClinicalTrials.gov)	February 22, 2012	16/3/2011	Gene Therapy for Fanconi Anemia	Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)	Fanconi Anemia	Procedure: Bone Marrow Aspiration;Biological: Filgrastim;Biological: Genetically Engineered Hematopoietic Stem Progenitor Cells;Other: Laboratory Biomarker Analysis;Procedure: Leukapheresis;Drug: Methylprednisolone;Drug: Plerixafor;Drug: Prednisone	Fred Hutchinson Cancer Research Center	National Heart, Lung, and Blood Institute (NHLBI);Rocket Pharma Limited	Active, not recruiting	4 Years	N/A	All	3	Phase 1	United States